US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19.

Finberg, Robert W; Ashraf, Madiha; Julg, Boris; Ayoade, Folusakin; Marathe, Jai G; Issa, Nicolas C; Wang, Jennifer P; Jaijakul, Siraya; Baden, Lindsey R; Epstein, Carol

Finberg, Robert W; Ashraf, Madiha; Julg, Boris; Ayoade, Folusakin; Marathe, Jai G; Issa, Nicolas C; Wang, Jennifer P; Jaijakul, Siraya; Baden, Lindsey R; Epstein, Carol.

Afiliação

Finberg RW; University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Ashraf M; Houston Methodist Research Institute, Houston, Texas, USA.
Julg B; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, USA.
Ayoade F; University of Miami Miller School of Medicine, Miami, Florida, USA.
Marathe JG; Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Issa NC; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Wang JP; University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Jaijakul S; Houston Methodist Research Institute, Houston, Texas, USA.
Baden LR; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Epstein C; FUJIFILM Pharmaceuticals USA, Inc., Cambridge, Massachusetts, USA.

Open Forum Infect Dis ; 8(12): ofab563, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34888401

Palavras-chave

COVID-19; favipiravir; hospitalized; human

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google